Watson Rises as Generic Pain Patch Gets Regulatory Approval
This article is for subscribers only.
Watson Pharmaceuticals Inc. rose after the drugmaker’s generic lidocaine patch to treat pain associated with shingles received U.S. regulatory approval.
Watson increased 6 percent to $83.32 at 4 p.m. New York time, its biggest gain in four months.